Page 50 - Read Online
P. 50

Page 12 of 14         Galli et al. J Cancer Metastasis Treat 2022;8:48  https://dx.doi.org/10.20517/2394-4722.2022.19

               might be an option that could be discussed with the patient. In such cases, the balance between a watchful
               surveillance vs. an ND with its potential adverse events and long-term sequelae should be individually
               weighed.


               DECLARATIONS
               Authors’ contributions
               Conception and design: Nisa L, Giger R
               Data acquisition and analysis: Galli J, Nisa L
               Manuscript drafting: Galli J, Giger R, Nisa L
               All authors revised the final version, approved the submitted version and have agreed both to be personally
               accountable for the author’s own contributions and do ensure that questions related to the accuracy or
               integrity of any part of the work, even ones in which each author was not personally involved, are
               appropriately investigated, resolved, and the resolution is documented in the literature.


               Availability of data and materials
               Anonymized version of the data is available upon reasonable request.


               Financial support and sponsorship
               None.


               Conflicts of interest
               All authors declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               Our institutional and regional ethics committee (Cantonal Ethics Committee of Bern) granted approval to
               perform the present study. Patients’ data were stored anonymously in a database only accessible to the
               principal investigators of this study.


               Consent for publication
               In line with the Declaration of Helsinki and the Swiss Ordinance on Human Research, all patients provided
               written consent for research and publication.

               Copyright
               © The Author(s) 2022.

               REFERENCES
               1.       Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.  DOI  PubMed
               2.       Steuer CE, El-Deiry M, Parks JR, Higgins KA, Saba NF. An update on larynx cancer. CA Cancer J Clin 2017;67:31-50.  DOI
                   PubMed
               3.       Wolf GT, Fisher SG, Hong WK, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with
                   advanced laryngeal cancer. N Engl J Med 1991;324:1685-90.  DOI  PubMed
               4.       Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal
                   cancer. N Engl J Med 2003;349:2091-8.  DOI  PubMed
               5.       Barthel SW, Esclamado RM. Primary radiation therapy for early glottic cancer. Otolaryngol Head Neck Surg 2001;124:35-9.  DOI
                   PubMed
               6.       Deng J, Ridner SH, Dietrich MS, et al. Prevalence of secondary lymphedema in patients with head and neck cancer. J Pain Symptom
                   Manage 2012;43:244-52.  DOI  PubMed
               7.       Straub JM, New J, Hamilton CD, Lominska C, Shnayder Y, Thomas SM. Radiation-induced fibrosis: mechanisms and implications for
                   therapy. J Cancer Res Clin Oncol 2015;141:1985-94.  DOI  PubMed  PMC
               8.       Ridner SH, Dietrich MS, Niermann K, Cmelak A, Mannion K, Murphy B. A prospective study of the lymphedema and fibrosis
                   continuum in patients with head and neck cancer. Lymphat Res Biol 2016;14:198-205.  DOI  PubMed  PMC
   45   46   47   48   49   50   51   52   53   54   55